BLRXBioLineRx Ltd.

Nasdaq biolinerx.com


$ 0.63 $ -0.02 (-3.16 %)    

Tuesday, 17-Sep-2024 11:46:21 EDT
QQQ $ 473.83 $ -2.14 (-0.45 %)
DIA $ 417.12 $ -0.12 (-0.03 %)
SPY $ 563.14 $ 0.30 (0.05 %)
TLT $ 100.82 $ -0.51 (-0.5 %)
GLD $ 237.35 $ -1.32 (-0.55 %)
$ 0.6198
$ 0.64
-- x --
-- x --
$ 0.63 - $ 0.64
$ 0.51 - $ 2.30
173,007
na
44.9M
$ 1.40
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 biolinerx-launches-mobilization-matters-a-digital-resource-for-people-with-multiple-myeloma-preparing-for-stem-cell-collection-patient-survey-currently-underway-in-partnership-with-the-healthtree-foundation-data-expected-in-q1-2025

Patient survey currently underway in partnership with the HealthTree Foundation; data expected in Q1 2025TEL AVIV, Israel and W...

 jones-trading-initiates-coverage-on-bioline-rx-with-buy-rating-announces-price-target-of-2

Jones Trading analyst Justin Walsh initiates coverage on BioLine Rx (NASDAQ:BLRX) with a Buy rating and announces Price Targ...

 hc-wainwright--co-reiterates-buy-on-bioline-rx-maintains-21-price-target

HC Wainwright & Co. analyst Joseph Pantginis reiterates BioLine Rx (NASDAQ:BLRX) with a Buy and maintains $21 price target.

 hc-wainwright--co-reiterates-buy-on-bioline-rx-maintains-21-price-target

HC Wainwright & Co. analyst Joseph Pantginis reiterates BioLine Rx (NASDAQ:BLRX) with a Buy and maintains $21 price target.

 biolinerx-says-cash-cash-equivalents-and-short-term-bank-deposits-of-282m-will-be-sufficient-to-fund-operations-as-currently-planned-into-2025

The company says this amount does not include $6.0 million in gross proceeds received from a registered direct offering and a $...

 biolinerx-discloses-abstract-on-pilot-study-data-from-phase-2-combination-clinical-trial-evaluating-motixafortide-in-first-line-pancreatic-cancer-at-american-society-of-clinical-oncology-2024-annual-meeting

New analysis of biopsy samples demonstrated a significant increase in CD8+ T-cell density in tumors from all 11 patients trea...

 hc-wainwright--co-reiterates-buy-on-bioline-rx-maintains-21-price-target

HC Wainwright & Co. analyst Joseph Pantginis reiterates BioLine Rx (NASDAQ:BLRX) with a Buy and maintains $21 price target.

 biolinerx-announces-6m-registered-direct-offering-of-75m-ads-and-warrants-to-purchase-up-to-an-aggregate-of-75m-adss-at-a-combined-purchase-price-of-080-per-ads-and-accompanying-warrant

BioLineRx Ltd. (NASDAQ:BLRX) (TASE: BLRX) ("BioLineRx" or the "Company"), a commercial stage biopharmaceutical ...

 hc-wainwright--co-reiterates-buy-on-bioline-rx-maintains-21-price-target

HC Wainwright & Co. analyst Joseph Pantginis reiterates BioLine Rx (NASDAQ:BLRX) with a Buy and maintains $21 price target.

 bioline-rx-q4-eps-015-beats-022-estimate-sales-480m

BioLine Rx (NASDAQ:BLRX) reported quarterly losses of $(0.15) per share which beat the analyst consensus estimate of $(0.22) by...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION